Attention Deficit Hyperactivity Disorder Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Attention Deficit Hyperactivity Disorder stocks.

Attention Deficit Hyperactivity Disorder Stocks Recent News

Date Stock Title
May 26 LLY Got $500? 3 Pharma Stocks to Buy and Hold Forever
May 26 LLY Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
May 26 LLY The Biggest Publicly Traded Biotech Company
May 25 LLY 3 High-Flying Stocks That Could Soar Even More
May 25 LLY Elon Musk Says Ozempic 'Will Become Very Cheap' After New Comedy Special Paints It As Weight Loss Drug Only Wealthy People Can Afford
May 24 LLY Dow Jones Futures: Market Rally Narrows; Dow Giants Lead 7 Stocks Near Buy Points
May 24 NLSP NLS Pharmaceutics receives non-compliance notice from Nasdaq
May 24 NLSP NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
May 24 LLY Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds
May 24 LLY Eli Lilly to Invest Another $5.3 Billion in Indiana Manufacturing Site
May 24 LLY Ether ETF approved, Live Nation antitrust suit: Morning Brief
May 24 SUPN Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
May 24 LLY Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro
May 24 LLY Eli Lilly to spend another $5.3B on production site for Mounjaro, Zepbound
May 24 LLY Stocks open in the green, Dow hopeful to claw back losses
May 24 LLY Lilly invests further $5.3 billion in new Indiana site as obesity drug demand soars
May 24 LLY Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines
May 24 LLY Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
May 24 LLY Eli Lilly to Spend $5.3 Billion to Make More Mounjaro, Zepbound
May 24 LLY Jim Cramer Says This Basic Materials Stock Is 'Too Dicey,' Shares His Take On Arista Networks
Attention Deficit Hyperactivity Disorder

Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity, or difficulty controlling behavior which is not appropriate for a person's age. The symptoms appear before a person is twelve years old, are present for more than six months, and may cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention span for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the exact cause is unknown in the majority of cases. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015 it is estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults inner restlessness rather than hyperactivity may occur. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normative behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend that medications and behavioral therapy be used together as a first-line therapy, except in preschool-aged children. Stimulant medication therapy is not recommended as a first-line therapy in preschool-aged children in either guideline. Treatment with stimulants is effective for at least 14 months; however, their long term effectiveness is unclear. Adults often develop coping skills which make up for some or all of their impairments.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention-deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

Browse All Tags